State-of-the-Art PaperCompelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?: A Clinical Perspective
Key Words
Abbreviations and Acronyms
Cited by (0)
Actelion, Gilead, Lilly/Icos, Pfizer, Novartis, and United Therapeutics have provided funding to the University of Chicago to support Dr. Gomberg-Maitland’s conduct of clinical trials. Dr. Gomberg-Maitland has served as a consultant/participant on data safety monitoring board/steering committee for clinical trials for Actelion, Gilead, Medtronic, Pfizer, and United Therapeutics; and has a patent filed entitled “Compositions and Methods for Treating Pulmonary Hypertension” for the use of sorafenib in pulmonary hypertension, WO/2007/087575. Dr. Dufton is a previous employee of, consultant for, and stock owner in Gilead Sciences. Dr. Oudiz receives research support or grants, is a consultant, and is on the Speakers’ Bureau for Actelion, Bayer, Gilead, LungRx, Pfizer, and United Therapeutics. Dr. Benza has received grant support and honoraria from Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics, Pfizer, and Lung Rx.